# Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers

> **NCT07686367** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (estimated)

## Conditions studied

- Metastatic Myxoid Liposarcoma
- Metastatic Synovial Sarcoma
- Unresectable Myxoid Liposarcoma
- Unresectable Synovial Sarcoma

## Interventions

- **BIOLOGICAL:** Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT07686367
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-23
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686367, "Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*